New York CNN —As prescriptions for weight-loss and diabetes drugs skyrocket, so too has revenue for drugmakers Novo Nordisk and Eli Lilly. On Thursday, Novo Nordisk, the Denmark-based company behind Ozempic and Wegovy, reported a 29% increase in sales to $8.4 billion for the third quarter. The pharmaceutical companies are two of the biggest beneficiaries of the recent weight-loss drug frenzy, with Novo Nordisk catapulting to Europe’s most valuable company in September. Novo Nordisk reported that its obesity care sales grew 174% in the first nine months of 2023, mainly driven by US demand. The success of Novo Nordisk and Eli Lilly’s drugs has inspired other companies to dive into the prescription weight-loss business, including WeightWatchers, now known as WW International.

---

Persons: Eli Lilly, Mounjaro, Wegovy, Novo, –, Eli Lilly’s Organizations: New, New York CNN, drugmakers Novo Nordisk, Novo Nordisk, Novo Nordisk catapulting, International Locations: New York, Denmark, United States, Novo